Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
10.7499/j.issn.1008-8830.2107153
- Author:
Wei-Ping DENG
1
Author Information
1. Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China (Luo P, Email: luoping1011@126. com).
- Publication Type:Review
- Keywords:
Belimumab;
Child;
Lupus nephritis;
Systemic lupus erythematosus
- MeSH:
Antibodies, Monoclonal, Humanized;
Child;
Humans;
Immunosuppressive Agents;
Kidney;
Lupus Erythematosus, Systemic/drug therapy*;
Lupus Nephritis;
Treatment Outcome
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(10):1069-1074
- CountryChina
- Language:English
-
Abstract:
Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs, and lupus nephritis (LN) is the most common renal complication of SLE. Belimumab is a fully humanized monoclonal antibody that can reduce the number of B cells, thereby reducing the formation of autoantibodies. Belimumab can improve SLE response index and SLE disease activity score and delay the progression of LN in both adults and children and thus plays an important role in the treatment of SLE and LN. This article reviews related research reports of belimumab used in the treatment of children and adults with SLE in China and overseas and analyzes the efficacy and safety of belimumab in pediatric patients, in order to provide a reference for the clinical application of belimumab in children with SLE.
